Bruce Mullen, MD
Physical Medicine & Rehabilitation · Carson City, NVNPI 1083781702
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,039 of the $21,588 with a category attached, or 65.0%. 25 manufacturers reported payments, led by Abbott at 36.9% of the total. Among physical medicine & rehabilitation clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 583 payments — averaging $37.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$8K
- Saluda Medical Americas, Inc.$6K
- Nevro Corp.$3K
- Boston Scientific$1K
- SPR Therapeutics, Inc$671
- Medtronic$583
- plus $3K from 19 others
What the payments were for
- Travel & lodging$7,49135%
- Food & beverage$14,03965%
- Education$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 223 | $7,959 |
| Saluda Medical Americas, Inc. | 94 | $5,876 |
| Nevro Corp. | 78 | $2,785 |
| Boston Scientific | 25 | $1,036 |
| SPR Therapeutics, Inc | 6 | $671 |
| Medtronic | 26 | $583 |
| Stimwave Technologies Incorporated | 11 | $555 |
| Collegium Pharmaceutical, Inc. | 36 | $425 |
| Biodelivery Sciences International, Inc. | 34 | $312 |
| AbbVie(2 entities) | 6 | $273 |
| Pfizer | 13 | $243 |
| Si-bone, Inc. | 4 | $211 |
| Curonix LLC | 3 | $166 |
| Eisai Inc. | 7 | $115 |
| Biotissue Holdings Inc. | 1 | $80 |
| Biohaven Pharmaceuticals, Inc. | 4 | $69 |
| Almatica Pharma LLC | 3 | $53 |
| Amniox Medical, Inc. | 2 | $44 |
| Painteq LLC | 1 | $35 |
| Bioventus LLC | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Vertex | 1 | $18 |
| Amgen | 1 | $14 |
| Shionogi Inc | 1 | $13 |
| Averitas Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evoke$2,480
- Neuromodulation Dspsbls and Accs$1,941
- Evoke SCS$1,865
- Senza Spinal Cord Stimulation System$1,419
- Proclaim Family of SCS IPGs$1,356
- SPRINT PNS System$613
- StimQ Freedom-4A Receiver Kit Channel A US w/ Receiver$408
- GENERAL PAIN MANAGEMENT$289
- Proclaim IPG$282
- StimQ Receiver Stimulator Kit Channel A US w Receiver$204
- Freedom 4A Receiver Kit Channel A US w Receiver$204
- Freedom 8A Receiver Kit Channel A US w Receiver$204
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$150
- PROCLAIM$123
- UBRELVY$123
- Swift-Lock SCS$119
How this compares
$21,588 in reported general payments places this provider in the 95th percentile of 98 physical medicine & rehabilitation providers in Nevada.
See all physical medicine & rehabilitation providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 282 | $41,936 |
| Nurtec OdtRimegepant Sulfate | 14 | $19,968 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 561 | $14,181 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $7,831 |
| Xtampza ErOxycodone Myristate | 14 | $7,576 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 203 | $7,137 |
| Oxycodone Hcl | 246 | $5,559 |
| OxycontinOxycodone Hcl | 13 | $5,435 |
| Celecoxib | 63 | $4,590 |
| Gabapentin | 276 | $3,778 |
| Buprenorphine | 20 | $3,404 |
| Pregabalin | 139 | $2,287 |
| Morphine Sulfate ErMorphine Sulfate | 100 | $2,242 |
| Triazolam | 19 | $2,014 |
| Tramadol Hcl | 165 | $1,288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $243 | $19,96814 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $425 | $7,57614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 98 physical medicine & rehabilitation providers in Nevada.
Other physical medicine & rehabilitation in Carson City
- Michael ShapiroCarson City$27K
- Peter CostaCarson City$113
- Alexander ImasHenderson$34K
- Sharlene SuReno$15K
- Casey KeatingReno$13K
- Kyle WentzLas Vegas$8K
- Andrew HsuReno$7K
- Edmund PasimioLas Vegas$6K
- Daniel KrauchukLas Vegas$6K
- Jesson BaumgartnerReno$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.